The influence of miR-34a expression on stemness and cytotoxic susceptibility of breast cancer stem cells

被引:8
|
作者
Zhang, Hongyao [1 ]
Li, Ning [1 ]
Zhang, Jiahui [1 ]
Jin, Fengjiao [1 ]
Shan, Meihua [1 ]
Qin, Junfang [1 ]
Wang, Yue [1 ]
机构
[1] Nankai Univ, Sch Med, Tianjin, Peoples R China
基金
中国国家自然科学基金;
关键词
Cytotoxic susceptibility; ligand; miR-34a; Notch1; DOWN-REGULATION; NKG2D RECEPTOR; SELF-RENEWAL; SUPPRESSES; GROWTH; NOTCH; TUMORIGENICITY; MACROPHAGES; METASTASIS; ACTIVATION;
D O I
10.1080/15384047.2016.1177678
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this study, we investigate the effect of miR-34a expression and biological characteristics of breast cancer stem cells (BCSCs). The mammospheres were formed from murine breast cancer cell line 4T1 and regarded as murine BCSCs. Identification of stemness molecules and cloning experiments validate the biological characteristics of BCSCs we have established. We showed that miR-34a, as a tumor suppressor, could separately reduce the stemness of BCSCs and activate the cytotoxic susceptibility of BCSCs to natural killer (NK) cells in vitro via down regulating the expression of Notch1 signaling molecules. Moreover, miR-34a could completely restrain established mice breast tumor xenografts in vivo in the NOD/SCID mice that have functional NK cells at a normal level, whereas it was less effective in NOD/SCID/ CD122/IL-2R mice that do not have functional NK cells. We conclude that miR-34a is a crucial, dual tumor suppressor and BCSCs-targeting immunotherapeutic agent and has shown efficacy in the treatment of murine breast cancer. The results also suggest that impaired NK cells could contribute to the resistance to therapies.
引用
收藏
页码:614 / 624
页数:11
相关论文
共 50 条
  • [1] miR-34a a micromanager of cancer stemness and resistance in NSCLC
    MacDonagh, L.
    Toland, S.
    Gray, S. G.
    Gallagher, M.
    Ffrench, B.
    Gasch, C.
    Reidy, M.
    Finn, S.
    Cuffe, S.
    O'Byrne, K.
    Barr, M. P.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 1) : S23 - S23
  • [2] Role of microRNA miR-34a in liver cancer stem cells
    Gong, Lu-Lu
    Yang, Shu-Li
    Zhang, Guo-Feng
    Wu, Jia-Cheng
    Lin, Rui-Xin
    BANGLADESH JOURNAL OF PHARMACOLOGY, 2016, 11 (02) : 333 - 336
  • [3] INVOLVEMENT OF MiR-34A IN RESISTANCE OF BREAST CANCER CELLS TO DOCETAXEL
    Kastl, Lena
    Schofield, Andrew C.
    EJC SUPPLEMENTS, 2010, 8 (06): : 20 - 21
  • [4] LncRNA SNHG7 Mediates the Chemoresistance and Stemness of Breast Cancer by Sponging miR-34a
    Li, Zhi-hua
    Yu, Ni-si
    Deng, Qing
    Zhang, Yulu
    Hu, Yang-yang
    Liu, Gang
    Huang, Kedi
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [5] miR-34a expression in human breast cancer is associated with drug resistance
    Li, Zhi-Hua
    Weng, Xueling
    Xiong, Qiu-Yun
    Tu, Jian-Hong
    Xiao, An
    Qiu, Wei
    Gong, Yu
    Hu, Er-Wei
    Huang, Songyin
    Cao, Ya-Li
    ONCOTARGET, 2017, 8 (63) : 106270 - 106282
  • [6] Targeting pancreatic cancer stem cells by epigenetic regulation of miR-34a
    Shankar, Sharmila
    Srivastava, Rakesh
    CANCER RESEARCH, 2011, 71
  • [7] Expression and role of miR-34a in bladder cancer
    Wang, Wei
    Li, Tan
    Han, Guang
    Li, Ying
    Shi, Li-hua
    Li, Hui
    INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS, 2013, 50 (02): : 87 - 92
  • [8] Expression of microRNA miR-34a inhibits leukemia stem cells and its metastasis
    Wang, S.
    Wang, T.
    Li, M. -Z.
    Cheng, X. -L.
    Li, X. -L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (13) : 2878 - 2883
  • [9] The miR-34a is down-regulated in breast cancer and breast stem cells and a potential to eradicating breast cancer via a systemic delivery of a VISA-miR-34a nanoparticle system
    Xie, X.
    Li, L.
    Xie, X.
    Wei, W.
    Kong, Y.
    Wu, M.
    Yang, L.
    Gao, J.
    Xiao, X.
    Tang, J.
    Xie, Z.
    Wang, X.
    Liu, P.
    Li, X.
    Guo, J.
    CANCER RESEARCH, 2012, 72
  • [10] Neoadjuvant chemotherapy in breast cancer patients induces expression of miR-34a and miR-122
    Freres, R.
    Josse, C.
    Bovy, N.
    Boukerroucha, M.
    Struman, I.
    Bours, V.
    Jerusalem, G.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 53 - 54